The vocabulary of the German hospital market — explained precisely.

Account-based marketing is a B2B marketing discipline in which individual, named target organisations — specific German university hospitals or hospital purchasing groups, for example — are treated as markets in their own right and addressed individually. Instead of reach campaigns, ABM creates precise touchpoints with identified decision-makers.

AEO and GEO describe the practice of optimising content so that it is cited in AI-generated answers. Where classic SEO targets a list of results, AEO and GEO are about being mentioned in the synthesised answers of ChatGPT, Perplexity, Claude and Google AI Overviews. The two terms are often used interchangeably in the industry.

Answer engines are systems that respond to a natural-language question with a synthesised answer instead of a list of results. They draw their information from indexed sources and cite them partly visibly, partly only implicitly. For manufacturers this means that visibility is no longer decided by ranking position, but by whether the brand is citable as a source.

The BfArM is an independent federal authority within the portfolio of the Federal Ministry of Health, based in Bonn. In the medical device field it is responsible for market surveillance, the assessment of serious incidents, the handling of field safety corrective actions and the national implementation of the MDR.

A DiGA is a CE-certified app or browser-based application approved for medical purposes (detection, monitoring, treatment, alleviation) that is reimbursed by statutory health insurers once it has been listed in the BfArM's DiGA directory. Listing requires successful evidence of positive healthcare effects.

The DRG system — G-DRG in Germany — classifies every hospital case into a flat-rate case group, which the hospital is reimbursed for within a defined corridor, independently of the actual length of stay and resource consumption. DRG logic determines which products a hospital can afford to use. The mechanism will be familiar from Medicare's MS-DRGs; in Germany, the G-DRG covers acute inpatient care across all payers.

Purchasing groups such as Sana, Helios, Asklepios, Agaplesion, P.E.G. and Prospitalia pool the procurement of dozens to hundreds of hospitals and negotiate framework agreements with manufacturers. In function they resemble a US group purchasing organisation; some are the procurement arms of hospital chains, others independent cooperatives. Without a listing in one of the large purchasing groups, nationwide hospital supply is practically impossible to scale.

Manufacturers established outside the EU must appoint an EU authorised representative who formally assumes the obligations towards EU authorities: keeping the technical documentation available, communicating with authorities, cooperating on vigilance cases, and registering in Eudamed. The role cannot be delegated to a pure distributor. It goes considerably further than the FDA's U.S. Agent, whose remit is essentially a communication channel.

Eudamed is the database operated by the European Commission in which all medical devices marketed in the EU — together with their manufacturers, authorised representatives and importers — have to be registered. It has six modules (among them actor registration, UDI/device registration, notified bodies, market surveillance, vigilance and clinical investigations). Its phased rollout has been under way since 2018.

The G-BA is an independent body made up of representatives of the statutory health insurers, the hospitals, the panel physicians and the patient organisations. It issues binding directives on service provision and reimbursement in the German healthcare system — from new diagnostic and treatment methods (NUB) through to assessments of established methods.

GDP covers compliant practice for distributing healthcare products: controlled storage conditions, an unbroken cold chain, traceability, audits and staff training. Although GDP was originally written for medicinal products, it is the de facto standard for sterile and temperature-sensitive medical devices.

The HWG places tight limits above all on misleading and comparative advertising for medical devices, and on advertising aimed at lay audiences. Promises of cure, before-and-after depictions, misleading success rates and inadmissible designations are prohibited. Breaches can lead to cease-and-desist warnings, fines and sales bans.

The KHZG obliges German hospitals to digitalise across eleven funding areas, among them patient portals, digital nursing documentation, clinical risk management, telemedicine and IT security. The funds are allocated through the federal states, with strict assessment by the Institute for the Hospital Remuneration System (InEK).

KOLs shape the treatment pathways, guidelines, publications and specialist conferences of an indication. In Germany they are usually based at university hospitals or specialised maximum-care hospitals and are active in medical societies. Their recommendation can accelerate a product launch; their silence can delay it.

Listing readiness is more than CE conformity: a documented MDR pipeline (PRRC, Eudamed, vigilance), German translations, a DRG argument, GDP-compliant logistics, KOL references and a German EU authorised representative. Only once these six preconditions are in place together does the actual listing conversation begin.

German hospitals are grouped into four levels of care: basic, standard, specialist and maximum care. Maximum-care hospitals cover every medical specialty at the highest level of specialisation, are frequently affiliated with a university and run research of their own. They are the first addresses for innovative medical devices.

The MDR has replaced the earlier MDD and AIMDD directives since May 2021 and tightens the requirements for classification, clinical evaluation, post-market surveillance, vigilance, unique device identification (UDI) and the obligations of economic operators (manufacturer, EU authorised representative, importer, distributor). It applies directly in all EU member states. Unlike the FDA's 510(k) pathway, there is no clearance based on substantial equivalence to a predicate device; conformity is assessed against the regulation itself, in most classes by a notified body.

The MPDG, in force since May 2021, replaced the former Medical Devices Act (Medizinproduktegesetz, MPG) and contains the German implementing structure for the MDR: the responsibilities of the authorities (BfArM, PEI, state authorities), language requirements, administrative offences and criminal provisions, advertising rules (in conjunction with the HWG), and transitional arrangements.

PMS covers all activities by which a manufacturer gathers and evaluates findings from the real-world use of its device and feeds them back into risk management and clinical evaluation. The results go into the PMS plan and into either the PMS report (for Class I devices) or the PSUR (for devices in higher classes).

Every manufacturer — and in many cases the EU authorised representative as well — must designate at least one PRRC who is regulatorily qualified, either through a university degree in medicine, pharmacy or engineering, or through four years of professional experience in medical device regulation. Their responsibilities include conformity checks, the release of documents, vigilance reporting and the PSUR.

The PSUR summarises the PMS findings for a defined period: incidents, trends, corrective actions, clinical data and a reassessment of the benefit-risk ratio. It is transmitted via Eudamed to the competent authority — in Germany the BfArM — and forms the basis of ongoing market surveillance.

SEO covers technical levers (crawlability, performance, structured data), structural levers (information architecture, internal linking) and content levers (keyword strategy, semantic depth, authority). In B2B and medical device contexts, long-tail queries with deep intent dominate.

UDI consists of two components: the Device Identifier (UDI-DI), which uniquely identifies the product model, and the Production Identifier (UDI-PI), carrying lot, serial or expiry data. The UDI must appear on the device, on the packaging and in Eudamed. The issuing entities are GS1, HIBCC and IFA.

Germany has 36 university hospitals under 32 owners. They train the next generation of physicians, run clinical research, treat patients at the highest level of care, and are the natural anchor points for innovative medical devices and clinical studies.

Vigilance covers the structured capture, assessment and authority reporting of serious incidents and field safety corrective actions (FSCA). In Germany, reports are submitted via Eudamed to the BfArM, within the deadlines set out in Article 87(4) MDR (15 days as standard, 10 days in the event of death or an unanticipated serious deterioration in a person’s state of health, 2 days in the event of a serious public health threat).